RAPH Share Price Performance
US$0.22
-0.04 (-15.38%)
Price US$0.22
Share PriceUS$0.22
RAPH Community Narratives
There are no narratives available yet.
Recent RAPH News & Updates
No updates
Raphael Pharmaceutical Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.071
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -5.6%
Raphael Pharmaceutical Inc. Competitors
About RAPH
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. The company is headquartered in Tel Aviv-Jaffa, Israel.
Israeli Market Performance
- 7 Days: -1.7%
- 3 Months: 18.6%
- 1 Year: 67.6%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 1.7%, driven by losses in the Financials and Real Estate sectors of 1.8% and 2.9%, respectively. As for the longer term, the market has actually risen by 68% in the last year. Earnings are forecast to grow by 16% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading